title: Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance.
abstract: Recent advances in immunotherapy have demonstrated that single agent vaccines can be effective when given as primary prevention before exposure to the causative agent, and partially effective in some patients with existing cancer. However, as tumors develop and progress, tumor-induced immune suppression and tolerance present the greatest barrier to therapeutic success. Preneoplastic disease represents an important opportunity to intervene with tumor antigen-targeted vaccines before these mechanisms of immune evasion outpace efforts by the immune system to destroy precancerous cells. However, as we discuss in this review, emerging evidence suggests that procarcinogenic inflammatory changes occur early in cancer development, in both patients and mouse models of cancer progression. Defining early inhibitory signals within tumor microenvironments will yield insights that can eventually be used in the clinic to target these events and deliver treatments that can be used in addition to cancer vaccines to prevent premalignant and early invasive cancers.
authors: The Sidney Kimmel Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
authors: Bridget
authors: B
authors: Keenan
authors: Elizabeth M
authors: EM
authors: Jaffee
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D019496:Cancer Vaccines / Q000737:chemistry*; D018450:Disease Progression; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods; D007249:Inflammation; D009857:Oncogenes; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000473:pathology; D011230:Precancerous Conditions / Q000276:immunology* / Q000628:therapy*; D015398:Signal Transduction; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines
references: Clin Cancer Res. 2009 Jan 1;15(1):361-7
references: 19118066
references: Cancer Cell. 2004 Nov;6(5):447-58
references: 15542429
references: J Hepatobiliary Pancreat Surg. 2007;14(3):224-32
references: 17520196
references: J Immunol. 2010 Dec 1;185(11):7107-14
references: 21037100
references: Cancer Cell. 2012 Jun 12;21(6):822-35
references: 22698406
references: Cancer. 2012 Sep 1;118(17):4354-62
references: 22252842
references: Antiviral Res. 2012 Oct;96(1):36-50
references: 22841700
references: Cancer Sci. 2007 Dec;98(12):1930-5
references: 17892515
references: Br J Cancer. 2012 Oct 23;107(9):1445-50
references: 22955856
references: Cancer Res. 2007 Oct 1;67(19):9518-27
references: 17909062